Immune response induced by the TAT-conjugated influenza M2e in mice

다국어 초록 (Multilingual Abstract)

Matrix 2 protein ectodomain (M2e) of influenza virus appears to be a promising vaccine candidate because its sequence is highly conserved among virus strains. However, M2e is too meager to induce a strong immune response by itself. Several approaches are being used to increase the antigenicity of M2e. In an effort to enhance the M2e-specific immune response, we generated a TAT-conjugated M2e recombinant protein. Seven-week-old BALB/c mice were divided into three groups and transcutaneously immunized with 100 μg TAT-8×M2e (TAT conjugated with eight copies of M2e) and 8×M2e (eight copies of M2e) proteins on days 1, 15 and 29. The control mice were injected with PBS on the same days. Antibody titers specific for M2e were measured using indirect ELISA. Mice immunized with the TAT-8×M2e and 8×M2e proteins developed almost the same levels of M2e-specific total IgG and IgG1 antibodies. However, a higher level of M2e-specific IgG2a was observed in mice immunized with TAT-8×M2e than in those immunized with 8×M2e. These results suggest that TAT has an adjuvant effect that induces a Th1-type immune response. Therefore, the TAT-M2e vaccine can be applied to animals as a new influenza vaccine for enhancement of Th1-type immune responses.

참고문헌 (Reference)

1 De Filette M, "Universal influenza A vaccine: optimization of M2-based constructs" 337 (337): 149-161, 2005

2 Schotsaert M, "Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments" 8 (8): 499-508, 2009

3 Chauhan A, "The taming of the cell penetrating domain of the HIV Tat: Myths and realities" 117 (117): 148-162, 2007

4 Chen X, "The delivery of HBcAg via Tat-PTD enhances specific immune response and inhibits Hepatitis B virus replication in transgenic mice" 28 (28): 3913-3919, 2010

5 Ryser HJ, "The cellular uptake of horseradish peroxidase and its poly(lysine) conjugate by cultured fibroblasts is qualitatively similar despite a 900-fold difference in rate" 113 (113): 167-178, 1982

6 Bettosini F, "The C terminus of the nucleoprotein of influenza A virus delivers antigens transduced by Tat to the trans-Golgi network and promotes an efficient presentation through HLA class I" 79 (79): 15537-15546, 2005

7 Fawell S, "Tat-mediated delivery of heterologous proteins into cells" 91 (91): 664-668, 1994

8 Ho A, "Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo" 61 (61): 474-477, 2001

9 Du L, "Research and development of universal influenza vaccines" 12 (12): 280-286, 2010

10 Wadia JS, "Protein transduction technology" 13 (13): 52-56, 2002

11 Bae MY, "Protective anti-tumour immune responses by murine dendritic cells pulsed with recombinant Tat-carcinoembryonic antigen derived from Escherichia coli" 157 (157): 128-138, 2009

12 Fiore AE, "Prevention and control of influenza with vaccines: Recommendations of the advisory committee on immunization practices (ACIP), 2010" 59 (59): 1-62, 2010

13 Huleatt JW, "Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin" 26 (26): 201-214, 2008

14 Mitsui H, "Polyarginine-mediated protein delivery to dendritic cells presents antigen more efficiently onto MHC class I and class II and elicits superior antitumor immunity" 126 (126): 1804-1812, 2006

15 Kim SG, "Modification of CEA with both CRT and TAT PTD induces potent anti-tumor immune responses in RNA-pulsed DC vaccination" 26 (26): 6433-6440, 2008

16 Snapper CM, "Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production" 236 (236): 944-947, 1987

17 Zebedee SL, "Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions" 62 (62): 2762-2772, 1988

18 Jegerlehner A, "Influenza A vaccine based on the extracellular domain of M2: Weak protection mediated via antibody-dependent NK cell activity" 172 (172): 5598-5605, 2004

19 Liu W, "High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity" 23 (23): 366-371, 2004

20 Neumann G, "Emergence and pandemic potential of swine-origin H1N1 influenza virus" 459 (459): 931-939, 2009

21 Mukai Y, "Creation of novel protein transduction domain (PTD) mutants by a phage displaybased high-throughput screening system" 29 (29): 1570-1574, 2006

22 Zebedee SL, "Characterization of the influenza virus M2 integral membrane protein and expression at the infected-cell surface from cloned cDNA" 56 (56): 502-511, 1985

23 Reid AH, "Characterization of the 1918 "Spanish" influenza virus matrix gene segment" 76 (76): 10717-10723, 2002

24 Poon GM, "Cell-surface proteoglycans as molecular portals for cationic peptide and polymer entry into cells" 35 (35): 788-793, 2007

25 Eliasson DG, "CTA1-M2e- DD: A novel mucosal adjuvant targeted influenza vaccine" 26 (26): 1243-1252, 2008

26 De Filette M, "An influenza A vaccine based on tetrameric ectodomain of matrix protein 2" 283 (283): 11382-11387, 2008

27 Fiers W, "A "universal" human influenza A vaccine" 103 (103): 173-176, 2004